drugset / Trial / NCT05516914
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
This trial is an open and multicenter phase Ib/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.
Timeline
- Start
- 2022-09-01
- Primary completion
- 2026-01-30
- Completion
- 2026-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LBL-007 Injection | Unknown | — | Intravenous |
| Subject | Tislelizumab Injection | Unknown | — | Intravenous |
| Background | Cisplatin Injection | Unknown | — | Intravenous |
| Background | Docetaxel injection | Unknown | — | Intravenous |
| Background | Gemcitabine Hydrochloride for Injection | Unknown | — | Intravenous |